


**Amendments to the Claims:**


1. (Original) A compound of the formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B independently represent CH<sub>2</sub> or O, with the proviso that A and B are not simultaneously O;

Cy represents one of the following



optionally substituted by one to three groups selected from hydroxy, halogen, C<sub>1-6</sub>alkyl,

C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>alkylamino and amino;

R<sup>1</sup> and R<sup>2</sup> are independently selected from hydroxy, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy,

C<sub>1-6</sub>haloalkyl and C<sub>3-8</sub> cycloalkyl;

n represents an integer from 0-4;

X is hydrogen, hydroxy, halogen or C<sub>1-6</sub> alkoxy;

Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy and C<sub>1-6</sub>haloalkyl;

Z is CH or N; and

p represents an integer from 0-5 when Z is CH or 0-4 when Z is N,

when p represents 2 or more, two of R<sup>2</sup>s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring.

2. (Currently Amended) A compound according to claim 1 where wherein A and B represent carbon atoms.

3. (Currently Amended) A compound according to claim 1 where wherein A represents O and B represents C.

4. (Currently Amended) A compound according to claim 1 where wherein A represents C and B represents O.

5. (Currently Amended) A compound according to any one of claims 1 to 4 where Cy is selected from optionally further substituted 4-hydroxyphenyl, 1*H*-pyrazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazole-6-yl and 2-hydroxy-5-pyridyl.

6. (Currently Amended) A compound according to any one of claims 1 to 5 where wherein Cy represents 4-hydroxyphenyl, optionally further substituted by fluoro or methyl.

7. (Currently Amended) A compound according to any one of claims 1 to 6 where wherein n represents 0.

8. (Currently Amended) A compound according to any one of claims 1 to 7 wherein R<sup>2</sup> represents methoxy, chloro, fluoro or methyl.

9. (Currently Amended) A compound according to any one of claims 1 to 8 wherein p represents 0-2.

10. (Currently Amended) A compound according to any one of claims 1 to 9 wherein X is hydrogen or hydroxy.

11. (Currently Amended) A compound according to any one of claims 1 to 10 wherein Y is selected from methylene, oxyethyleneoxy, oxymethylene, methyleneoxy, methyleneoxymethylene, ethyleneoxy, oxyethylene and oxy.

12. (Currently Amended) A compound according to any one of claims 1 to 11 wherein Y is para located to and in a *trans* configuration to X.

13. (Currently Amended) A compound of formula (I) selected from the group consisting of:  
4-Hydroxy-N-{{[cis-4-(phenoxyethyl)cyclohexyl]methyl}benzamide;  
4-Hydroxy-N-{{[cis-4-[(4-methoxyphenoxy)methyl]cyclohexyl]methyl}benzamide;  
N-{{[cis-4-(Benzyl)oxy)cyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[cis-4-[(4-Chlorobenzyl)oxy]cyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[cis-4-[(3-Chlorobenzyl)oxy]cyclohexyl]methyl}-4-hydroxybenzamide;  
4-Hydroxy-N-{{[cis-4-(4-methoxyphenoxy)cyclohexyl]methyl}benzamide;  
N-{{[cis-4-(4-Chlorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;  
4-Hydroxy-N-{{[1-hydroxy-4-(phenoxyethyl)cyclohexyl]methyl}benzamide;  
N-{{[trans-4-[(4-Fluorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[trans-4-[(3-Fluorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[trans-4-[(2-Fluorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[trans-4-[(2,6-Difluorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[trans-4-[(3,5-Difluorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[trans-4-[(3-Chlorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
N-{{[trans-4-[(4-Chlorophenoxy)methyl]-1-hydroxycyclohexyl]methyl}-4-hydroxybenzamide;  
4-Hydroxy-N-{{[trans-1-hydroxy-4-[(2-methylphenoxy)methyl]cyclohexyl]methyl}benzamide;

4-Hydroxy-N-(*{trans}-1-hydroxy-4-[(3-methylphenoxy)methyl]cyclohexyl*)methyl)benzamide;  
4-Hydroxy-N-(*{trans}-1-hydroxy-4-[(4-methylphenoxy)methyl]cyclohexyl*)methyl)benzamide;  
*N*-(*{trans}-4-[(Benzyl)oxy]methyl*-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;  
*N*-[*(trans*-4-[(2-Fluorobenzyl)oxy]methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;  
*N*-[*(trans*-4-[(4-Fluorobenzyl)oxy]methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;  
4-Hydroxy-N-[*{trans}-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl*]methyl)benzamide;  
*N*-[*{trans}-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{trans}-4-[2-(3-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{trans}-4-[2-(4-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{trans}-4-(Benzyl)oxy-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{trans}-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{cis}-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{trans}-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl*]methyl]-3-fluoro-4-hydroxybenzamide;  
*N*-[*{cis}-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl*]methyl]-3-fluoro-4-hydroxybenzamide;  
(+)-4-hydroxy-*N*-[*[5S-(phenoxy)methyl]tetrahydro-2H-pyran-2S-yl*]methyl)benzamide;  
(-)-4-hydroxy-*N*-[*[5R-(phenoxy)methyl]tetrahydro-2H-pyran-2R-yl*]methyl)benzamide;  
4-hydroxy-*N*-[*[5S-(benzyloxymethyl]tetrahydro-2H-pyran-2S-yl*]methyl)benzamide;  
4-hydroxy-*N*-[*[5R-(benzyloxymethyl]tetrahydro-2H-pyran-2R-yl*]methyl)benzamide;  
(-)-4-Hydroxy-*N*-[*[(3R,6S)-6-(phenoxy)methyl]tetrahydro-2H-pyran-3-yl*]methyl)benzamide;  
(+)-4-Hydroxy-*N*-[*[(3S,6R)-6-(phenoxy)methyl]tetrahydro-2H-pyran-3-yl*]methyl)benzamide;  
*N*-[*{trans}-4-[(2-Fluorobenzyl)oxy]-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
3-Fluoro-*N*-[*{trans}-4-[2-(2-fluorophenoxy)ethyl]-1-hydroxycyclohexyl*]methyl)-4-hydroxybenzamide;  
*trans* - *N*-[*{4-(4-chlorophenoxy)cyclohexyl}*]methyl]-3-fluoro-4-hydroxybenzamide;  
*cis* - *N*-[*{4-(4-chlorophenoxy)cyclohexyl}*]methyl]-3-fluoro-4-hydroxybenzamide;  
*N*-[*{cis}-4-(4-Fluorophenoxy)cyclohexyl*]methyl)-4-hydroxybenzamide;  
3-Fluoro-*N*-[*{cis}-4-(4-fluorophenoxy)cyclohexyl*]methyl)-4-hydroxybenzamide;  
*N*-[*{trans}-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl*]methyl)-1*H*-pyrazole-4-carboxamide;  
4-hydroxy-*N*-[*{cis}-4-(2-phenylethoxy)cyclohexyl*]methyl)benzamide;  
2-fluoro-4-hydroxy-*N*-[*{trans}-1-hydroxy-4-(phenoxy)methyl]cyclohexyl*]methyl)benzamide;  
*N*-[*{trans}-4-[(benzyloxy)methyl]-1-hydroxycyclohexyl*]methyl)-3-fluoro-4-hydroxybenzamide;  
*N*-[*{cis}-4-[(Benzyl)oxy]methyl]cyclohexyl]methyl)-4-hydroxybenzamide*

3-Fluoro-4-hydroxy-N-*{[trans-1-hydroxy-4-(phenoxyethyl)cyclohexyl]methyl}*benzamide;  
3-Fluoro-4-hydroxy-N-*{[trans-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl]methyl}*benzamide;  
3-Fluoro-N-*{[(trans-4-[(4-fluorobenzyl)oxy]methyl)-1-hydroxycyclohexyl]methyl}*-4-hydroxybenzamide;  
3-Fluoro-N-*{[(trans-4-[(2-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl]*-4-hydroxybenzamide;  
3-Fluoro-N-*{[(trans-4-[(4-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl]*-4-hydroxybenzamide;  
4-Hydroxy-N-*{[(trans-1-hydroxy-4-[(5-methylpyridin-2-yl)oxy]methyl)cyclohexyl]methyl}*benzamide;  
N-*{[(trans-4-Benzyl-1-hydroxycyclohexyl)methyl]*-4-hydroxybenzamide;  
3-fluoro-N-*{[(trans-4-[(2-fluorobenzyl)oxy]methyl)-1-hydroxycyclohexyl)methyl]*-4-hydroxybenzamide;  
6-Hydroxy-N-*{[(cis-4-(2-phenethoxy)cyclohexyl)methyl]}*nicotinamide;  
N-*{[(cis-4-(2-Phenylethoxy)cyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(cis-4-(Phenoxyethyl)cyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(cis-4-(2-Phenoxyethyl)cyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(cis-4-[(3-Fluorophenoxy)methyl)cyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(cis-4-[(4-Fluorophenoxy)methyl)cyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(2R,5R)-5-[(4-Fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(cis-4-(4-Methoxybenzyl)cyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
3-Amino-N-*{[(cis-4-benzylcyclohexyl)methyl]}*-1*H*-pyrazole-4-carboxamide;  
N-*{[(2R,5R)-5-[(4-Chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl}*-1*H*-pyrazole-4-carboxamide;  
3-Amino-N-*{[(2R,5R)-5-[(4-fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl}*-1*H*-pyrazole-4-carboxamide;  
3-Amino-N-*{[(2R,5R)-5-[(4-chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl}*-1*H*-pyrazole-4-carboxamide; and  
3-Amino-N-*{[(2R,5R)-5-[(4-ethylphenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl}*-1*H*-pyrazole-4-carboxamide;  
or a pharmaceutically acceptable salt or solvate thereof.

14. (Currently Amended) A pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1-to-13, together with a pharmaceutically acceptable excipient.

15. (Currently Amended) A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1-to-14, for use as a medicament.

16. (Cancel)

17. (Cancel)

18. (Currently Amended) A method of treatment of a mammal, including a human being, to treat a disease for which an NMDA NR2B antagonist is indicated, including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof, as defined in any one of claims 1-to-13 and 14, respectively.

19. (Currently Amended) A method according to claim 18 wherein the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.

20. (Currently Amended) A combination of a compound of the formula (I), as defined in any one of claims 1-13, and another pharmacologically active agent.